DRG 839 Overview

DRG 839 covers inpatient stays where the principal reason includes chemotherapy and acute leukemia is present as a secondary diagnosis without a Complication or Comorbidity or Major Complication or Comorbidity. This Diagnosis-Related Group applies to patients receiving systemic anti-neoplastic therapy during an admission and distinguishes payment when acute leukemia does not add higher complication levels. It matters for Medicare payment because it groups clinical complexity tied to chemotherapy administration separately from higher-paying categories that require documented complications. Accurate coding of the principal procedure and secondary diagnosis is central to correct assignment and reimbursement.

• Acute inpatient supportive care intervention trials assessing strategies to reduce treatment-related complications during hospitalization for chemotherapy in patients with acute leukemia recorded as a secondary diagnosis; these studies enroll patients receiving cytotoxic or targeted chemotherapy who develop febrile neutropenia, mucositis, transfusion needs, or other acute toxicities requiring inpatient management. They evaluate interventions such as optimized antimicrobial stewardship protocols, neutropenia management pathways, blood product utilization algorithms, or standardized symptom-control bundles to shorten length of stay and reduce ICU transfers. Results are directly relevant to providers and payers because improved inpatient complication management can lower resource utilization, readmission risk, and DRG-level costs for this high-acuity cohort.
• Comparative effectiveness and dosing strategy studies comparing chemotherapy scheduling, supportive medication timing, or anticoagulation/antiemetic regimens for hospitalized adult and older-adult patients whose principal admission is for chemotherapy with acute leukemia listed as a secondary diagnosis; these trials often use pragmatic designs in real-world inpatient settings to determine which approaches produce fewer adverse events or complications. The focus is on balancing efficacy of cancer-directed chemotherapy with minimization of hospitalization length, transfusion needs, and organ dysfunction in medically complex patients. Findings inform clinical pathways and payer coverage decisions by identifying regimens or protocols that achieve similar oncologic outcomes with lower inpatient resource consumption and complication rates.
• Post-discharge outcomes and care-transition studies that follow patients discharged after inpatient chemotherapy with acute leukemia as a secondary diagnosis to evaluate readmission drivers, outpatient supportive care needs, and long-term functional recovery; these cohort or randomized trials test interventions such as enhanced discharge planning, outpatient neutropenia monitoring programs, or home-based nursing support. They target patients at high risk for early readmission or emergency visits due to infection, bleeding, or uncontrolled symptoms, with the goal of reducing 30-day readmissions and cumulative post-discharge costs. Payers and hospital systems use this evidence to design discharge bundles and case management policies that can decrease downstream expenditures tied to this DRG.